Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
| Autor: | Erlandson KM; Department of Medicine, Division of Infectious Diseases, University of Colorado, Anschutz Medical Campus, Aurora, Colorado (K.M.E.)., Geng LN; Department of Medicine, Stanford University, Stanford, California (L.N.G., M.G., U.S.)., Selvaggi CA; Massachusetts General Hospital Biostatistics, Boston, Massachusetts (C.A.S., T.T., A.S.F.)., Thaweethai T; Massachusetts General Hospital Biostatistics, Boston, Massachusetts (C.A.S., T.T., A.S.F.)., Chen P; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, and Women's Guild Lung Institute at Cedars-Sinai Medical Center, New York, New York (P.C.)., Erdmann NB; Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (N.B.E., P.A.G.)., Goldman JD; Swedish Center for Research and Innovation, Providence Swedish Medical Center, and Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington (J.D.G.)., Henrich TJ; Division of Experimental Medicine, University of California San Francisco, San Francisco, California (T.J.H.)., Hornig M; CORe Community Inc., and Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York (M.H.)., Karlson EW; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts (E.W.K.)., Katz SD; Department of Medicine, NYU Grossman School of Medicine, New York, New York (S.D.K.)., Kim C; RECOVER Initiative, New York, New York (C.K., R.L.)., Cribbs SK; Department of Medicine, Emory University School of Medicine, and Atlanta Veterans Affairs Medical Center, Atlanta, Georgia (S.K.C.)., Laiyemo AO; Department of Medicine, Division of Gastroenterology, Howard University College of Medicine, Washington, DC (A.O.L.)., Letts R; RECOVER Initiative, New York, New York (C.K., R.L.)., Lin JY; Department of Emergency Medicine, University of Illinois Chicago, Chicago, Illinois (J.Y.L.)., Marathe J; Department of Medicine, Division of Infectious Diseases, Boston University Medical Campus, Boston, Massachusetts (J.M.)., Parthasarathy S; Department of Medicine, University of Arizona, Tucson, Arizona (S.P.)., Patterson TF; Department of Medicine, University of Texas Health San Antonio, San Antonio, Texas (T.F.P., B.S.T.)., Taylor BD; RECOVER Initiative, New York, New York, and American Heart Association, Health Strategies, Atlanta, Georgia (B.D.T.)., Duffy ER; Boston Medical Center, Boston, Massachusetts (E.R.D.)., Haack M; Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts (M.H.)., Julg B; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, Massachusetts (B.J.)., Maranga G; Department of Population Health, NYU Grossman School of Medicine, New York, New York (G.M.)., Hernandez C; Departments of Pediatrics and Medicine, Case Western Reserve University, Cleveland, Ohio (C.H.)., Singer NG; Departments of Pediatrics and Medicine and Division of Rheumatology, Case Western Reserve University, Cleveland, Ohio (N.G.S.)., Han J; Department of Medicine, Emory University School of Medicine, and Grady Hospital, Atlanta, Georgia (J.H.)., Pemu P; Department of Medicine, Morehouse School of Medicine, Atlanta, Georgia (P.P.)., Brim H; Department of Pathology, Howard University, Washington, DC (H.B.)., Ashktorab H; Department of Medicine, Howard University, Washington, DC (H.A.)., Charney AW; Icahn School of Medicine at Mount Sinai Hospital, New York, New York (A.W.C., J.W., J.L.)., Wisnivesky J; Icahn School of Medicine at Mount Sinai Hospital, New York, New York (A.W.C., J.W., J.L.)., Lin JJ; Icahn School of Medicine at Mount Sinai Hospital, New York, New York (A.W.C., J.W., J.L.)., Chu HY; Division of Global Health, University of Washington, Seattle, Washington (H.Y.C.)., Go M; Department of Medicine, Stanford University, Stanford, California (L.N.G., M.G., U.S.)., Singh U; Department of Medicine, Stanford University, Stanford, California (L.N.G., M.G., U.S.)., Levitan EB; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama (E.B.L.)., Goepfert PA; Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (N.B.E., P.A.G.)., Nikolich JŽ; Department of Immunobiology, University of Arizona College of Medicine-Tucson, and Arizona Center on Aging, Tucson, Arizona (J.ŽN.)., Hsu H; Banner University Medical Center, Tucson, Arizona (H.H.)., Peluso MJ; Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California (M.J.P., J.D.K.)., Kelly JD; Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California (M.J.P., J.D.K.)., Okumura MJ; Departments of Medicine and Pediatrics, University of California San Francisco, San Francisco, California (M.O.)., Flaherman VJ; Department of Pediatrics, University of California San Francisco, San Francisco, California (V.J.F.)., Quigley JG; Department of Medicine, Division of Hematology/Oncology, University of Illinois Chicago, Chicago, Illinois (J.G.Q.)., Krishnan JA; Department of Medicine, University of Illinois Chicago, Chicago, Illinois (J.A.K.)., Scholand MB; Department of Medicine, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah (M.B.S., R.H.)., Hess R; Department of Medicine, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah (M.B.S., R.H.)., Metz TD; Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah (T.D.M.)., Costantine MM; Division of Maternal Fetal Medicine, The Ohio State University, Columbus, Ohio (M.M.C.)., Rouse DJ; Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island (D.J.R.)., Taylor BS; Department of Medicine, University of Texas Health San Antonio, San Antonio, Texas (T.F.P., B.S.T.)., Goldberg MP; Department of Neurology, University of Texas Health San Antonio, San Antonio, Texas (M.P.G.)., Marshall GD; Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi (G.D.M.)., Wood J; The Gill Heart and Vascular Institute and Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky (J.W.)., Warren D; Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska (D.W.)., Horwitz L; Department of Population Health, NYU Grossman School of Medicine, and Center for Healthcare Innovation and Delivery Science, NYU Langone Health, New York, New York (L.H.)., Foulkes AS; Massachusetts General Hospital Biostatistics, Boston, Massachusetts (C.A.S., T.T., A.S.F.)., McComsey GA; Departments of Pediatrics and Medicine, Case Western Reserve University, and University Hospitals Cleveland Medical Center, Cleveland, Ohio (G.A.M.). |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of internal medicine [Ann Intern Med] 2024 Sep; Vol. 177 (9), pp. 1209-1221. Date of Electronic Publication: 2024 Aug 13. |
| DOI: | 10.7326/M24-0737 |
| Abstrakt: | Background: There are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC). Objective: To investigate clinical laboratory markers of SARS-CoV-2 and PASC. Design: Propensity score-weighted linear regression models were fitted to evaluate differences in mean laboratory measures by prior infection and PASC index (≥12 vs. 0). (ClinicalTrials.gov: NCT05172024). Setting: 83 enrolling sites. Participants: RECOVER-Adult cohort participants with or without SARS-CoV-2 infection with a study visit and laboratory measures 6 months after the index date (or at enrollment if >6 months after the index date). Participants were excluded if the 6-month visit occurred within 30 days of reinfection. Measurements: Participants completed questionnaires and standard clinical laboratory tests. Results: Among 10 094 participants, 8746 had prior SARS-CoV-2 infection, 1348 were uninfected, 1880 had a PASC index of 12 or higher, and 3351 had a PASC index of zero. After propensity score adjustment, participants with prior infection had a lower mean platelet count (265.9 × 10 9 cells/L [95% CI, 264.5 to 267.4 × 10 9 cells/L]) than participants without known prior infection (275.2 × 10 9 cells/L [CI, 268.5 to 282.0 × 10 9 cells/L]), as well as higher mean hemoglobin A Limitation: Whether differences in laboratory markers represent consequences of or risk factors for SARS-CoV-2 infection could not be determined. Conclusion: Overall, no evidence was found that any of the 25 routine clinical laboratory values assessed in this study could serve as a clinically useful biomarker of PASC. Primary Funding Source: National Institutes of Health. Competing Interests: Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M24-0737. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|